Glycopyrrolate is a Small Molecule owned by Novartis, and is involved in 40 clinical trials, of which 39 were completed, and 1 is ongoing.
Glycopyrrolate is a muscarinic receptor antagonist (LAMA, M3). Muscarinic receptor regulation of airway smooth muscle tone is enhanced in asthma and COPD by increased expression and enhanced function of signaling molecules essential for muscarinic receptor mediated airway smooth muscle contraction and by exaggerated release of neuronal acetylcholine due to neuronal mechanisms associated with inflammation.
The revenue for Glycopyrrolate is expected to reach a total of $85m through 2029. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Glycopyrrolate NPV Report.
Glycopyrronium bromide (Seebri / NVA237 / AD237 / Enurev / Tovanor / Seebri Breezhaler / Seebri Neohaler) is a quaternary ammonium derivative acts as bronchodilator. It is formulated as capsules with powder for inhalational route of administration. Glycopyrrolate bromide is indicated for the treatment of asthma, chronic obstructive pulmonary disease (COPD) including chronic bronchitis and /or emphysema.
The drug candidate was under development for asthma.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – Glycopyrrolate
|Highest Development Stage|